Navigation Links
Pregis Announces First Quarter 2009 Financial Results
Date:5/12/2009

g of period 41,179 34,989 ------ ------ Cash and cash equivalents, end of period $42,356 $42,511 ------- ------- Pregis Holding II Corporation Supplemental Information (Unaudited) Calculation of Adjusted EBITDA ("Consolidated Cash Flow") Twelve Months Ended March 31, (unaudited) ---------------------------- (dollars in thousands) 2009 2008 ---- ---- Net loss of Pregis Holding II Corporation $(54,866) $(10,298) Interest expense, net of interest income 45,713 46,044 Income tax expense (8,243) 6,766 Depreciation and amortization 50,275 56,663 ------ ------ EBITDA 32,879 99,175 Other non-cash charges (income): Unrealized foreign currency transaction losses (gains), net 21,175 (5,061) Non-cash stock based compensation expense 1,210 663 Non-cash asset impairment charge 20,354 403 Other non-cash expenses, primarily fixed asset disposals and write-offs 427 - Net unusual or nonrecurring gains or losses: Restructuring, severance and related expenses 17,298 4,830 Curtailment gain (3,736) - Nonrecurring charges related to acquisitions and dispositions - 5,214 Other unus
'/>"/>
SOURCE Pregis Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Pregis Corporation Appoints New President of Protective Packaging North America
2. Pregis Announces Investor Conference Call to Review 2007 Fourth Quarter and Full Year Financial Results
3. Pregis Announces Fouth Quarter and Full Year 2007 Financial Results
4. Pregis Announces First Quarter 2008 Financial Results
5. Pregis Announces Second Quarter 2008 Financial Results
6. Pregis Announces Investor Conference Call to Review 2008 Third Quarter Financial Results
7. Pregis Announces Third Quarter 2008 Financial Results
8. Pregis Announces Investor Conference Call to Review Fourth Quarter and Full Year 2008 Financial Results
9. Pregis Announces Fourth Quarter and Full Year 2008 Financial Results
10. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
11. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Scientists uncover secrets of potential bioterror virus 2Health News:Exagen Diagnostics Names John Alsobrook, Ph.D., Vice President and Chief Operating Officer 2Health News:A Drug That Receives Regulatory Approval for Cognitive Impairment Associated With Schizophrenia Would Earn a Higher Patient Share in the United States Than in Europe 2Health News:A Drug That Receives Regulatory Approval for Cognitive Impairment Associated With Schizophrenia Would Earn a Higher Patient Share in the United States Than in Europe 3Health News:St. Mary Medical Center Opens New Cardiovascular Catheterization Labs Reaffirming Role as a Regional Leader in Cardiovascular Medicine 2Health News:St. Mary Medical Center Opens New Cardiovascular Catheterization Labs Reaffirming Role as a Regional Leader in Cardiovascular Medicine 3Health News:St. Mary Medical Center Opens New Cardiovascular Catheterization Labs Reaffirming Role as a Regional Leader in Cardiovascular Medicine 4Health News:St. Mary Medical Center Opens New Cardiovascular Catheterization Labs Reaffirming Role as a Regional Leader in Cardiovascular Medicine 5Health News:FDA Clears New Immune Response Claim for the CryoValve(R) SG Pulmonary Human Heart Valve 2Health News:FDA Clears New Immune Response Claim for the CryoValve(R) SG Pulmonary Human Heart Valve 3Health News:Stratus Technologies Signs Allen Technologies as Newest Channel Partner for High Availability Avance Software 2Health News:Stratus Technologies Signs Allen Technologies as Newest Channel Partner for High Availability Avance Software 3
Breaking Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2ARKRAY, Inc. Announces Partnership With scil animal care company for the SPOTCHEM(TM) EZ Analyzer 2Be overweight and live longer 59643 1Springer and WINFOCUS found new journal 59641 1Springer and WINFOCUS found new journal 59641 2New findings on the formation of body pigment 59639 1